Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome

L. Chilton, R. K. Hills, C. J. Harrison, A. K. Burnett, D. Grimwade, Anthony Moorman

Research output: Contribution to journalReview article

Abstract

Chromosome gain is frequent in acute myeloid leukemia (AML) and is counted alongside structural abnormalities when determining karyotype complexity. However, there are few studies investigating the cytogenetic profile and outcome of patients with a hyperdiploid karyotype (49-65 chromosomes, HK). We identified 221 (14%) patients with HK out of 1563 patients with three or more chromosomal abnormalities. HK was not associated with sex, white cell count and secondary disease status, but was more prevalent among children (22% vs 13%). The pattern of chromosomal gain and loss was non-random and chromosomes 8, 13 and 21 were the most frequently gained. Three distinct subgroups (numerical, structural and adverse) were identified with differential outcome: 5-year cumulative incidence of relapse of 52%, 68% and 76%, respectively (P=0.008). Patients in the adverse subgroup had poorer survival compared with patients with only numerical abnormalities (adjusted hazard ratio: 2.01 (95% confidence interval: 1.43-2.83), P=0.0002). This outcome heterogeneity was similar among children and adults. In conclusion, AML patients with a HK should not automatically be assigned to the adverse cytogenetic risk group on the basis of complexity. Instead they should be assessed for the presence of specific chromosomal abnormalities, which are known to harbour an adverse effect.

Original languageEnglish (US)
Pages (from-to)321-328
Number of pages8
JournalLeukemia
Volume28
Issue number2
DOIs
StatePublished - Feb 1 2014
Externally publishedYes

Fingerprint

Polyploidy
Acute Myeloid Leukemia
Cytogenetics
Chromosomes
Karyotype
Chromosome Aberrations
Chromosomes, Human, Pair 13
Chromosomes, Human, Pair 21
Chromosomes, Human, Pair 8
Cell Count
Confidence Intervals
Recurrence
Survival
Incidence

Keywords

  • acute myeloid leukemia
  • complex karyotype
  • cytogenetics
  • hyperdiploid
  • prognosis

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. / Chilton, L.; Hills, R. K.; Harrison, C. J.; Burnett, A. K.; Grimwade, D.; Moorman, Anthony.

In: Leukemia, Vol. 28, No. 2, 01.02.2014, p. 321-328.

Research output: Contribution to journalReview article

Chilton, L. ; Hills, R. K. ; Harrison, C. J. ; Burnett, A. K. ; Grimwade, D. ; Moorman, Anthony. / Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. In: Leukemia. 2014 ; Vol. 28, No. 2. pp. 321-328.
@article{d17b5733bb844522933e32eecbafe793,
title = "Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome",
abstract = "Chromosome gain is frequent in acute myeloid leukemia (AML) and is counted alongside structural abnormalities when determining karyotype complexity. However, there are few studies investigating the cytogenetic profile and outcome of patients with a hyperdiploid karyotype (49-65 chromosomes, HK). We identified 221 (14{\%}) patients with HK out of 1563 patients with three or more chromosomal abnormalities. HK was not associated with sex, white cell count and secondary disease status, but was more prevalent among children (22{\%} vs 13{\%}). The pattern of chromosomal gain and loss was non-random and chromosomes 8, 13 and 21 were the most frequently gained. Three distinct subgroups (numerical, structural and adverse) were identified with differential outcome: 5-year cumulative incidence of relapse of 52{\%}, 68{\%} and 76{\%}, respectively (P=0.008). Patients in the adverse subgroup had poorer survival compared with patients with only numerical abnormalities (adjusted hazard ratio: 2.01 (95{\%} confidence interval: 1.43-2.83), P=0.0002). This outcome heterogeneity was similar among children and adults. In conclusion, AML patients with a HK should not automatically be assigned to the adverse cytogenetic risk group on the basis of complexity. Instead they should be assessed for the presence of specific chromosomal abnormalities, which are known to harbour an adverse effect.",
keywords = "acute myeloid leukemia, complex karyotype, cytogenetics, hyperdiploid, prognosis",
author = "L. Chilton and Hills, {R. K.} and Harrison, {C. J.} and Burnett, {A. K.} and D. Grimwade and Anthony Moorman",
year = "2014",
month = "2",
day = "1",
doi = "10.1038/leu.2013.198",
language = "English (US)",
volume = "28",
pages = "321--328",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome

AU - Chilton, L.

AU - Hills, R. K.

AU - Harrison, C. J.

AU - Burnett, A. K.

AU - Grimwade, D.

AU - Moorman, Anthony

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Chromosome gain is frequent in acute myeloid leukemia (AML) and is counted alongside structural abnormalities when determining karyotype complexity. However, there are few studies investigating the cytogenetic profile and outcome of patients with a hyperdiploid karyotype (49-65 chromosomes, HK). We identified 221 (14%) patients with HK out of 1563 patients with three or more chromosomal abnormalities. HK was not associated with sex, white cell count and secondary disease status, but was more prevalent among children (22% vs 13%). The pattern of chromosomal gain and loss was non-random and chromosomes 8, 13 and 21 were the most frequently gained. Three distinct subgroups (numerical, structural and adverse) were identified with differential outcome: 5-year cumulative incidence of relapse of 52%, 68% and 76%, respectively (P=0.008). Patients in the adverse subgroup had poorer survival compared with patients with only numerical abnormalities (adjusted hazard ratio: 2.01 (95% confidence interval: 1.43-2.83), P=0.0002). This outcome heterogeneity was similar among children and adults. In conclusion, AML patients with a HK should not automatically be assigned to the adverse cytogenetic risk group on the basis of complexity. Instead they should be assessed for the presence of specific chromosomal abnormalities, which are known to harbour an adverse effect.

AB - Chromosome gain is frequent in acute myeloid leukemia (AML) and is counted alongside structural abnormalities when determining karyotype complexity. However, there are few studies investigating the cytogenetic profile and outcome of patients with a hyperdiploid karyotype (49-65 chromosomes, HK). We identified 221 (14%) patients with HK out of 1563 patients with three or more chromosomal abnormalities. HK was not associated with sex, white cell count and secondary disease status, but was more prevalent among children (22% vs 13%). The pattern of chromosomal gain and loss was non-random and chromosomes 8, 13 and 21 were the most frequently gained. Three distinct subgroups (numerical, structural and adverse) were identified with differential outcome: 5-year cumulative incidence of relapse of 52%, 68% and 76%, respectively (P=0.008). Patients in the adverse subgroup had poorer survival compared with patients with only numerical abnormalities (adjusted hazard ratio: 2.01 (95% confidence interval: 1.43-2.83), P=0.0002). This outcome heterogeneity was similar among children and adults. In conclusion, AML patients with a HK should not automatically be assigned to the adverse cytogenetic risk group on the basis of complexity. Instead they should be assessed for the presence of specific chromosomal abnormalities, which are known to harbour an adverse effect.

KW - acute myeloid leukemia

KW - complex karyotype

KW - cytogenetics

KW - hyperdiploid

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=84893786272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893786272&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.198

DO - 10.1038/leu.2013.198

M3 - Review article

C2 - 23812419

AN - SCOPUS:84893786272

VL - 28

SP - 321

EP - 328

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -